In a report released today, Jack Meehan from Barclays maintained a Buy rating on Quidel Corp (QDEL), with a price target of $77. The company’s shares closed on Friday at $68.14.
According to TipRanks.com, Meehan is a 4-star analyst with an average return of 7.2% and a 64.4% success rate. Meehan covers the Healthcare sector, focusing on stocks such as Bio-Rad Laboratories, IQVIA Holdings Inc, and Syneos Health Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Quidel Corp with a $69.67 average price target.
See today’s analyst top recommended stocks >>
Quidel Corp’s market cap is currently $2.68B and has a P/E ratio of 37.29. The company has a Price to Book ratio of 6.31.
Based on the recent corporate insider activity of 72 insiders, corporate insider sentiment is negative on the stock. Earlier this month, Kenneth Buechler, a Director at QDEL sold 9,000 shares for a total of $598,500.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Quidel Corp. engages in the development, manufacture, and market of rapid diagnostic testing solutions. Its portfolio includes rapid immunoassays, cardiac immunoassays, specialized diagnostic solutions and molecular diagnostic solutions.
